Prognostic factor analysis indicated that worse baseline renal function, anemia, hypoalbuminemia, elevated BNP, initial dialysis dependency, and absence of cyclophosphamide treatment were associated with progression to ESRD at 3 years.<h4>Conclusion</h4>In patients with anti-GBM disease, the addition of RTX to standard therapy was associated with accelerated recovery of renal function, as evidenced by a shorter time to dialysis discontinuation. Here, NPPB is linked to anemia.